Literature DB >> 18277121

Update on rifampin and rifabutin drug interactions.

Anne M Baciewicz1, Cary R Chrisman, Christopher K Finch, Timothy H Self.   

Abstract

Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Examples of clinically relevant interactions demonstrated by recent reports include everolimus, atorvastatin, rosiglitazone/pioglitazone, celecoxib, clarithromycin, caspofungin, and lorazepam. To avoid a decreased therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Studies and cases of rifampin drug interactions continue to increase rapidly. This review is a timely reminder to clinicians to be vigilant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277121     DOI: 10.1097/MAJ.0b013e31814a586a

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  39 in total

1.  The ethics of a clinical trial when the protocol clashes with international guidelines.

Authors:  N T N Lan; N T N Thu; N H Duc; N N Lan; T T X Lien; N H Dung; A-M Taburet; D Laureillard; L Borand; C Quillet; D Lagarde; A Pym; C Connolly; C Lienhardt; C Rekacewicz; A D Harries
Journal:  Public Health Action       Date:  2013-06-21

2.  A relook at preventive therapy for tuberculosis in children.

Authors:  Varinder Singh; Soumya Patra
Journal:  Indian J Pediatr       Date:  2010-10-27       Impact factor: 1.967

3.  Overcoming the effect of rifampin on the tacrolimus metabolism by itraconazole administration in an allogeneic hematopoietic stem cell transplant recipient.

Authors:  Takehiko Mori; Yoshinobu Aisa; Jun Kato; Yukinori Nakamura; Takayuki Shimizu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2010-03-02       Impact factor: 2.490

Review 4.  Tuberculous pericarditis with and without HIV.

Authors:  Mpiko Ntsekhe; Bongani M Mayosi
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

5.  A physiologically based pharmacokinetic model of rifampin in mice.

Authors:  Michael A Lyons; Brad Reisfeld; Raymond S H Yang; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

6.  Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.

Authors:  Seong Mi Moon; Hye Yun Park; Byeong-Ho Jeong; Kyeongman Jeon; Soo-Youn Lee; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

Review 7.  Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Authors:  G L Birbeck; J A French; E Perucca; D M Simpson; H Fraimow; J M George; J F Okulicz; D B Clifford; H Hachad; R H Levy
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

8.  Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.

Authors:  J W C Alffenaar; W A Nienhuis; F de Velde; A T Zuur; A M A Wessels; D Almeida; J Grosset; O Adjei; D R A Uges; T S van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 9.  Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.

Authors:  Mario Regazzi; Anna Cristina Carvalho; Paola Villani; Alberto Matteelli
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

Review 10.  PXR antagonists and implication in drug metabolism.

Authors:  Sridhar Mani; Wei Dou; Matthew R Redinbo
Journal:  Drug Metab Rev       Date:  2013-02       Impact factor: 4.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.